tbuckley/cabot-search huggingface dataset:
Abstract 19609: Novel Wnt Signaling in Neonatal Heart During Perinatal Transition
Authors: Marlin Touma, Xuedong Kang, Ashly Cass, Xinshu Xiao, Yibin Wang
Journal: Circulation (2014)

Background:  Fetal to neonatal transition of the mammalian heart is an elaborate process, during which the neonatal cardiomyocytes undergo complete maturation, differentiation, and irreversible exit from the cell cycle. However, the molecular mechanisms that control the chamber specific- growth of postnatal heart are understudied. In particular, the permanent arrest of cardiomyocytes cycling remains mysterious both in terms of the etiology and the mechanisms.   Objectives:  To determine factors of chamber specificity in neonatal heart during postnatal growth and maturation.   Methods:  Deep RNA-seq (2x92nt) was performed on male newborn mouse left ventricle (LV) and right ventricle (RV) at P0, P3 and P7. Neonatal Rat Ventricular Myoctes (NRVM), Wnt11-siRNA, and recombinant Wnt11 (rWnt11) were used to achieve Wnt11 Inhibition and gain of function respectively In Vitro. Wnt11-Antisense oligo nucleotide was used to achieve In Vivo inhibition of Wnt11. Anti-Phospho histone3 (Ph3) was used to assess proliferation.   Results:  Extensive transcriptome analysis and experimental validation revealed distinct, chamber specific- patterns of temporal regulation of cell cycle genes and Wnt signaling during maturation. Specifically, an RV specific- induction of cell cycle genes was found to reciprocally correlate with a robust LV specific- enrichment of the non-canonical-Wnt11 at P7. Functional studies revealed enhancement of NRVM maturation markers and down-regulation of cell cycle genes in response to Wnt11 gain of function. In contrast, Wnt11 inhibition induced NRVM proliferation markers and reduced the size and the fraction of bi-nucleated cells supporting a functional impact of wnt11. Furthermore, InVivo inhibition of Wnt11 at late gestation enhanced Ph3 and cell cycle markers at P0 suggesting cellular proliferation.   Conclusions:  Our findings suggest novel molecular basis for chamber-specific programming of proliferation and maturation in neonatal heart, including differential enrichment of cell cycle genes and novel Wnt11-mediated signaling. Further mechanistic studies to decipher putative roles of Wnt11 signaling in LV vs. RV programming during maturation in Vivo will likely pave the way to novel chamber-specific therapeutic targets.
Abstract 10713: Decrease in Oxidative Stress Associated with Hyperbilirubinemia and Augmentation of Endothelial Function in Gilbert Syndrome
Authors: Tatsuya Maruhashi, Yukihito Higashi, Junko Soga, Naomi Idei, Noritaka Fujimura, Shinsuke Mikami, Yumiko Iwamoto, Masato Kajikawa, Takeshi Matsumoto, Ayumu Nakashima, Kensuke Noma, Hirofummi Tomiyama, Bonpei Takase, Akira Yamashina, Yasuki Kihara
Journal: Circulation (2012)

Background: Patients with Gilbert syndrome have mild unconjugated hyperbilirubinemia. It has been shown that bilirubin is an endogenous antioxidant. Therefore, patients with Gilbert syndrome are id...
Roflumilast combined with montelukast versus montelukast alone as add-on treatment in patients with moderate-to-severe asthma
Authors: Eric D. Bateman, Udo-Michael Goehring, Frank Richard, Henrik Watz
Journal: Journal of Allergy and Clinical Immunology (2016)

BackgroundRoflumilast, a selective phosphodiesterase 4 inhibitor, has been shown to provide modest improvements in lung function in patients with mild-to-moderate asthma, but its efficacy in patients with moderate-to-severe asthma has not been assessed. We hypothesized that this drug might provide benefit if combined with montelukast, a leukotriene receptor antagonist, in patients whose symptoms are uncontrolled by inhaled corticosteroids and long-acting β-agonists.ObjectiveWe sought to examine the efficacy, safety, and mode of action of the addition of roflumilast and montelukast versus montelukast alone in patients with moderate-to-severe asthma.MethodsIn a phase 2, randomized, double-blind, placebo-controlled, multiple-dose, 2-sequence, crossover study, 64 patients were randomized to receive 500 μg of roflumilast plus montelukast followed by placebo plus 10 mg of montelukast (sequence AB) or placebo plus 10 mg of montelukast followed by 500 μg of roflumilast plus 10 mg of montelukast (sequence BA). All patients had a diagnosis of bronchial asthma inadequately controlled by at least a medium-dose inhaled corticosteroid plus a long-acting β-agonist.ResultsThe analysis of FEV1 change from baseline to week 4 showed a statistically significant and clinically meaningful treatment difference of 100 mL for roflumilast plus montelukast versus placebo plus montelukast. Also, improvements in patient-reported outcomes and a reduction in urinary leukotriene E4 levels were observed during roflumilast plus montelukast treatment compared with placebo plus montelukast treatment. Adverse events were consistent with the known safety profile of roflumilast.ConclusionThe combination of roflumilast with montelukast compared with montelukast alone improved lung function and asthma control in patients with moderate-to-severe asthma and deserves further study for this indication.
Induction of Dendritic Cell Differentiation by Granulocyte-Macrophage Colony-Stimulating Factor, Stem Cell Factor, and Tumor Necrosis Factor α In Vitro From Lineage Phenotypes-Negative c-kit+ Murine Hematopoietic Progenitor Cells
Authors: Yi Zhang, Naofumi Mukaida, Jian-bin Wang, Akihisa Harada, Mariko Akiyama, Kouji Matsushima
Journal: Blood (1997)
Multimodality treatment on long-term outcome of intracranial germ cell tumors in children: A single institution study
Authors: R. Kebudi, E. Darendeliler, I. Ayan, O. Gorgun, F. Yaman Agaoglu, Y. Dizdar, F. Darendeliler, H. Emiroglu
Journal: Journal of Clinical Oncology (2009)

10063 Background: Intracranial germ cell tumors (iGCT) constitute 1% of all malignant neoplasms in children. The aim of this study is to evaluate the demographic characteristics, therapy, and long term outcome of children with iGCT in a single institution. Methods: 16 children (9 female, 7 male) with a median age of 11 years (10 months-18 yrs) treated for iGCT between 1990 and 2008 were evaluated retrospectively. They were treated according to our institutional protocol. Patients &gt; 13 years old with germinomas recieved radiotherapy alone (2520 cGy craniospinal/1980 cGy local boost), patients &lt;13 yrs old recieved 2 courses of etoposide, cisplatinum followed with cranial radiotherapy. Nongerminoma patients recieved 3 courses of bleomycine, etoposide, cisplatinum followed by 3600 cGy craniospinal / 1980 cGy local boost RT. Results: Presenting clinical features were diabetes insipidus (7), raised intracranial pressure (12), visual changes-oculomotor palsies (6), hypopituitarism (4). 8 had germinomas and 8 nongeminomatous GCT. Ten were suprasellar and 6 pineal. AFP and BHCG were evaluated at diagnosis and during therapy both in serum and CSF. Three had seeding in the spinal axis in MRI. One had widespead systemic metastasis. Three had a total resection, 12 had a biopsy, 1 was clinically/radiologically diagnosed, 5 had a shunt. Two nongerminamatous iGCT patients died: 1 of widespread disease in the intensive care unit at diagnosis, the other with progressive disease 18 months after diagnosis. Fourteen patients are alive at a median follow-up of 12 years (1–17 years) from diagnosis. One that had motor and mental retardation before diagnosis needs special care. All others have a moderate/good quality of life. One is married and has a child. Six are at school (2 in university). Five are employed. The patients are also followed up in the endocrinology clinic. One is recieving growth hormone. Conclusions: Cisplatin based chemotherapy and radiotherapy is successful and well tolerated in children with iGCT. The possibility of an early clinical diagnosis based on MRI and tumor markers and the use of modern neurosurgical techniques increases the chance of cure, gives a chance to reduce acute morbidity and further decrease late effects. No significant financial relationships to disclose.
Rituximab Plus Hypercvad Alternating with High Dose Methotrexate and Cytarabine for Patients with Newly Diagnosed Mantle Cell Lymphoma. A Multicenter Trial from GISL
Authors: Francesco Merli, Stefano Luminari, Fiorella Ilariucci, Caterina Stelitano, Mario Petrini, Nicola Di Renzo, Francesco Angrilli, Angelo Michele Carella, Elisa Barbolini, Massimo Federico
Journal: Blood (2008)
Phase II pilot trial of imatinib mesylate with weekly docetaxel in metastatic breast cancer
Authors: J. H. Barton, W. Liggett, M. Mainwaring, J. D. Hainsworth, L. Simons, D. R. Spigel, H. A. Burris III, D. A. Yardley
Journal: Journal of Clinical Oncology (2006)

10716 Background: Overexpression of platelet derived growth factor receptor (PDGFR) has been associated with breast cancer tumor progression and may serve as a potential target for therapy. Inhibition of PDGFR signaling in tumor stroma represents a novel strategy that has demonstrated enhanced chemotherapy antitumor effects, decreased tumor interstitial fluid pressure as well as increased tumor transcapillary transport. Imatinib mesylate (G) is a potent PDGFR tyrosine kinase antagonist. This phase II pilot study evaluates the feasibility, toxicity, and efficacy of imatinib administered with docetaxel as a strategy to enhance docetaxel’s chemotherapeutic effects in metastatic breast cancer (MBC). Methods: Eligibility requirements: 0–1 prior regimens for MBC, &gt; 6 months from prior adjuvant taxanes, RECIST measurable disease, ECOG PS 0–2, adequate organ function, &lt; G2 neuropathy. Treatment: docetaxel 30 mg/m 2 IV weekly 3 of 4 weeks. Imatinib mesylate 600 mg po QD. Pts were evaluated for response every 8 weeks; treatment continued until progression or toxicity. Results: 7 pts have been enrolled to date. Median age is 61, all with ECOG PS 0. 5 pts received prior adjuvant therapy; 2 pts received prior taxanes. 43% received prior hormonal therapy. Only 1 pt was ER+/PR+. Hematologic toxicity was mild, consisting only of G3/4 anemia in 2 pts and G3 thrombocytopenia in 1. No febrile neutropenia was noted. Nonhematologic toxicity was characterized primarily by G3 GI toxicity: 4 pts diarrhea, 3 N, V, 1 anorexia, 1 abdominal pain. This was attributed to imatinib in all but 1 pt, in whom both drugs were implicated. 2 pts were removed from treatment and 3 pts required dose reductions, all due to GI toxicity consisting of N, V, and diarrhea. 3 pts experienced dose interruptions and 2 pts exhibited disease progression. Conclusion: These early preliminary results demonstrate imatinib mesylate, in combination with weekly docetaxel as a strategy to inhibit breast cancer PDGFR signaling, is feasible. GI toxicity with this combination was prominent and warrants dose modifications. Updated toxicity and efficacy data will be presented. [Table: see text]
Zika Virus Infection Among U.S. Pregnant Travelers — August 2015–February 2016
Authors: Dana Meaney-Delman, Susan L. Hills, Charnetta Williams, Romeo R. Galang, Preetha Iyengar, Andrew K. Hennenfent, Ingrid B. Rabe, Amanda Panella, Titilope Oduyebo, Margaret A. Honein, Sherif Zaki, Nicole Lindsey, Jennifer A. Lehman, Natalie Kwit, Jeanne Bertolli, Sascha Ellington, Irogue Igbinosa, Anna A. Minta, Emily E. Petersen, Paul Mead, Sonja A. Rasmussen, Denise J. Jamieson
Journal: MMWR Morbidity and Mortality Weekly Report (2016)

After reports of microcephaly and other adverse pregnancy outcomes in infants of mothers infected with Zika virus during pregnancy, CDC issued a travel alert on January 15, 2016, advising pregnant women to consider postponing travel to areas with active transmission of Zika virus. On January 19, CDC released interim guidelines for U.S. health care providers caring for pregnant women with travel to an affected area, and an update was released on February 5. As of February 17, CDC had received reports of nine pregnant travelers with laboratory-confirmed Zika virus disease; 10 additional reports of Zika virus disease among pregnant women are currently under investigation. No Zika virus-related hospitalizations or deaths among pregnant women were reported. Pregnancy outcomes among the nine confirmed cases included two early pregnancy losses, two elective terminations, and three live births (two apparently healthy infants and one infant with severe microcephaly); two pregnancies (approximately 18 weeks' and 34 weeks' gestation) are continuing without known complications. Confirmed cases of Zika virus infection were reported among women who had traveled to one or more of the following nine areas with ongoing local transmission of Zika virus: American Samoa, Brazil, El Salvador, Guatemala, Haiti, Honduras, Mexico, Puerto Rico, and Samoa. This report summarizes findings from the nine women with confirmed Zika virus infection during pregnancy, including case reports for four women with various clinical outcomes. U.S. health care providers caring for pregnant women with possible Zika virus exposure during pregnancy should follow CDC guidelines for patient evaluation and management. Zika virus disease is a nationally notifiable condition. CDC has developed a voluntary registry to collect information about U.S. pregnant women with confirmed Zika virus infection and their infants. Information about the registry is in preparation and will be available on the CDC website.
High response rates in patients with advanced biliary tract cancer (BTC) using the oral fluoropyrimidine S-1
Authors: K. Uchida, K. Hayashi, M. Yamamoto, K. Takasaki
Journal: Journal of Clinical Oncology (2005)

4239 Purpose: S-1 is a newly developed oral fluoropyrimidine derivative with demonstrated activity against several tumor types. The aim of this study was to evaluate the feasibility and efficacy of S-1 administered as a single-agent and in combination with cisplatin, for the treatment of patients with BTC. Experimental design: A total of 26 patients with locally advanced or recurrent BTC (gallbladder 12, extrahepatic bile ducts 8, intrahepatic bile ducts 5, ampulla of Vater 1) were entered into this study. Sixteen patients were treated with S-1 alone. S-1 was administered twice daily for 28 days, followed by a 2-week period of no treatment. Ten patients were treated with S-1 plus weekly cisplatin. This regimen consisted of S-1 twice dairy for 21days and CDDP 30mg/m2 on Day 1 and Day 8, followed by a 2-week period of no treatment. BSA was used to determine the dose of S-1 administered, as follows: BSA<1.25m2, 40mg; 1.25–1.5m2, 50mg; >=1.5m2, 60mg. Results: Out of 16 patients treated with S-1 alone, objective tumor responses were observed in 2 patients (12.5%); 6 patients were no change and 8 patients were progressive disease. And Out of 10 patients treated with S-1 plus CDDP, objective tumor responses were observed in 4 patients (40.0%); 2 patients were no change and 4 patients were progressive disease. Median survival time (MST) was 284 days and 474 days respectively. One case of grade3 anorexia was observed among patients treated with S-1 alone. One grade3 hematotoxicity and one grade3 anorexia appeared among patients treated with S-1 plus CDDP. Conclusions: S-1 alone and S-1/CDDP combination chemotherapy showed promising activity with acceptable toxicities against BTC. Further evaluation of S-1 in patients with this disease is warranted. No significant financial relationships to disclose.
A subgroup analysis of the TROPIC trial exploring reason for discontinuation of prior docetaxel and survival outcome of cabazitaxel in metastatic castration-resistant prostate cancer (mCRPC).
Authors: J. S. De Bono, S. Oudard, M. Ozguroglu, S. Hansen, J. H. Machiels, L. Shen, A. O. Sartor
Journal: Journal of Clinical Oncology (2011)

4526^ Background: The Phase III TROPIC trial showed that cabazitaxel plus prednisone (CbzP) significantly improved overall survival (OS) compared with mitoxantrone plus prednisone (MP) in men with mCRPC whose disease progressed during or after treatment with a docetaxel regimen (Lancet 2010; 376:1147–54). We conducted a post hoc analysis of TROPIC to assess whether the survival benefit of CbzP was maintained in subgroups defined by the reason for discontinuation of prior docetaxel. Methods: The analysis included the 755 men randomized to receive either CbzP (n=378) or MP (n=377). Reason for discontinuation of prior docetaxel was documented in case report forms (disease progression, adverse events, completed treatment, other reasons). The Kaplan–Meier method was used to analyze OS, which was defined from the time of randomization to death (any cause). Unadjusted hazard ratios (HR) and 95% confidence intervals (CI) were calculated using the Cox proportional hazards model. Results: The majority of patients were randomized to TROPIC within 6 months of last docetaxel dose. Progression occurred during or within 3 months of last docetaxel dose in 72% of CbzP and 76% of MP patients. The proportion of randomized patients that discontinued prior docetaxel due to disease progression was similar (63% CbzP; 61% MP). In this subgroup, the median OS was 13.8 months with CbzP vs. 10.9 months with MP (HR 0.70; 95% CI 0.57–0.87). The survival benefit of CbzP over MP was also evident in the 286 patients (CbzP: n=139; MP: n=147) who discontinued prior docetaxel for a reason other than disease progression, with a median OS of 18.0 months with CbzP vs. 15.6 months with MP (HR 0.63; 95% CI 0.46–0.85). Analysis of the small subgroup of patients (CbzP: n=22; MP: n=26) who discontinued prior docetaxel due to an adverse event suggests a consistent improvement in OS (median 16.0 months CbzP; 14.8 months MP [HR 0.63; 95% CI 0.30–1.33]). Conclusions: This post hoc analysis suggests that the survival benefit of CbzP over MP in men with mCRPC is maintained irrespective of whether prior docetaxel treatment was discontinued due to disease progression.
Reducing Treatment-Related Morbidity and Mortality in Early-Stage Hodgkin’s Disease and Why the Recent Southwest Oncology Group Trial Is Not the Way to Go
Authors: Leonard R. Prosnitz
Journal: Journal of Clinical Oncology (2002)

Article Tools EDITORIALS Article Tools OPTIONS & TOOLS Export Citation Track Citation Add To Favorites Rights & Permissions COMPANION ARTICLES No companion articles ARTICLE CITATION DOI: 10.1200/JCO.2002.20.9.2225 Journal of Clinical Oncology - published online before print September 21, 2016 PMID: 11980993 Reducing Treatment-Related Morbidity and Mortality in Early-Stage Hodgkin’s Disease and Why the Recent Southwest Oncology Group Trial Is Not the Way to Go Leonard R. ProsnitzxLeonard R. ProsnitzSearch for articles by this author Show More Duke University Medical Center, Durham, NC https://doi.org/10.1200/JCO.2002.20.9.2225 First Page Full Text PDF Figures and Tables © 2002 by American Society of Clinical Oncology
Quantitation of Papova Virus Particles in Human Warts&lt;xref ref-type="fn" rid="fn1"&gt;2&lt;/xref&gt;
Authors: Julio G. Barrera-Oro, Kendall O. Smith, Joseph L. Melnick
Journal: JNCI Journal of the National Cancer Institute (1962)

The quantitative determination of virus particles in human warts is described. Human papilloma (wart) virus belongs to the papova virus group whose members are easily recognized by their distinctive fine structures: spheres of 45 mµ diameter with deoxyribonucleic acid cores and a capsid exhibiting cubic symmetry. Among 40 warts tested, the highest virus concentration found was 7.3 × 109 particles per mg. The lower limit of counting sensitivity was about 107 particles per mg of wart tissue. The number of particles in the tissue was not associated with age or sex of the patient. There appeared to be a correlation, however, between the age of the wart and the concentration of particles, with warts 6 to 12 months old containing the highest concentration of particles. Large differences were found, however, in the concentrations of particles in warts of the same age.
TREC to WHERE? Transdisciplinary Research on Energetics and Cancer
Authors: Kathryn H. Schmitz, Sarah Gehlert, Ruth E. Patterson, Graham A. Colditz, Jorge E. Chavarro, Frank B. Hu, Marian L. Neuhouser, Kathleen M. Sturgeon, Mark Thornquist, Deirdre Tobias, Linda C. Nebeling
Journal: Clinical Cancer Research (2016)

When information is exchanged across disciplinary boundaries, resources are shared, and discipline-specific approaches are altered to achieve a common scientific goal, we create a new intellectual space for transdisciplinary research. This approach, fostered heavily by multiple NCI-funded initiatives, has the potential to forge new understanding of major public health issues. By breaking down disciplinary barriers, we work toward making real, meaningful, and lasting forward motion in addressing key public health issues. One of the transdisciplinary initiatives of the NCI is TREC: Transdisciplinary Research on Energetics and Cancer. In this article, we review the goals and scope of TREC, as well as the ways in which the initiative promotes transdisciplinary science. A particular focus is on multiple examples of the most unique aspect of the initiative: the funding of developmental projects across multiple TREC centers, toward the goal of incubating high-risk science that has the potential to translate into major leaps forward in understanding energetics in cancer. As we enter an era of greater focus on investigator-initiated science, new approaches may be needed to ensure that the peer review process is not solely organized along disciplinary lines. Inclusion of expertise regarding transdisciplinarity, as well as representation from multiple scientific disciplines within a panel, may allow transdisciplinary research to receive an educated hearing. The body of researchers trained to work in a transdisciplinary research space is ideally suited to address these challenges.
Zika highlights need for ethical framework for developing vaccines for pregnant women
Authors: Gareth Iacobucci
Journal: BMJ (2016)

The recent outbreak of Zika virus infection highlights the need to prioritise the development and evaluation of vaccines for pregnant women, says a viewpoint article published in the JAMA .1

Zika virus is the third recent global infectious disease outbreak, following closely behind H1N1 flu and Ebola virus, that has had detrimental implications for pregnant women and their unborn children.

Saad Omer, of the department of global health at Emory University, Atlanta, and Richard Beigi, of the department of …
Modification of Diethylnitrosamine Liver Carcinogenesis With Phenobarbital but not With Immunosuppression2
Authors: John H. Wiesburger, Russell M. Madison, Jerrold M. Ward, Charlotte Viguerra, Elizabeth K. Weisburger
Journal: JNCI Journal of the National Cancer Institute (1975)

Administration of 40 ppm diethylnitrosamine (DENA) in the drinking water for 10 weeks to male Fischer rats led to hepatocellular carcinoma in 100%, with metastasis to the lung in 40%, of the animals living for the full experimental period of 20 weeks. Concurrent feeding of phenobarbital and DENA for 10 weeks produced cancer of the liver in 77% of the animals, but only 9% had metastases in the lung. A brief regimen of DENA for 4 weeks, followed by 16 weeks of observation, induced cancer of the liver in only 13% of the rats. Administration ofphenobarbital, begun 1 week after cessation of DENA intake and terminated at week 20, led to liver cancer in 64% of the rodents. Hydroxyurea had no effect on this enhancement. Treatment with a purified gamma fraction of antilymphocytic serum after the DENA did not influence the outcome. Thus phenobarbital given together with DENA reduced the severity of the carcinogenic process, but when it was given after the hepatocarcinogen, it increased the effect.
Efficacy of Egfr Tyrosine Kinase Inhibitors (Egfr Tkis) in Patients with Egfr-Mutated Non-Small Cell Lung Cancer Except Both Exon 19 Deletion and Exon 21 L858R: a Retrospective Analysis in Korea
Authors: J.H. Baek, Y.J. Min, E.K. Cho, B. Cho, J. Kim, J. Sun, M. Ahn, K. Park
Journal: Annals of Oncology (2014)